pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$NUVLNuvalent, Inc.

$NUVL123.960.00%
Cambridge, MA, USupdated 18d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
pre_registration: 2
2pre_registration
pre_registration
neladalkib
Non-Small Cell Lung Cancer
pre_registration
zidesamtinib
Non-Small Cell Lung Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 6, 2026
earnings
$NUVL123.960.00%
11d ago
Nuvalent, Inc. earnings
Nuvalent, Inc.
→
view all catalysts →

Active trials

  • phase3Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCrecruitingn=450
  • —Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumorsavailable
  • phase1A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)recruitingn=200
  • —Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumorsavailable
  • phase2A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)recruitingn=840
  • phase2A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)recruitingn=359

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 9, 26SELLPelish Henry E.· Chief Scientific Officer2,193 sh @ $104.27−$229K↗
  • Apr 9, 26SELLPelish Henry E.· Chief Scientific Officer900 sh @ $105.00−$95K↗
  • Apr 6, 26SELLPorter James Richard· President and CEO12,425 sh @ $103.78−$1.29M↗
  • Apr 6, 26SELLPorter James Richard· President and CEO11,354 sh @ $103.21−$1.17M↗
  • Apr 6, 26SELLPorter James Richard· President and CEO6,121 sh @ $104.78−$641K↗
  • Apr 6, 26SELLPorter James Richard· President and CEO100 sh @ $105.60−$11K↗
  • Apr 1, 26SELLBalcom Alexandra· Chief Financial Officer5,417 sh @ $105.30−$570K↗
  • Apr 1, 26SELLBalcom Alexandra· Chief Financial Officer3,544 sh @ $104.39−$370K↗
  • Apr 1, 26SELLBalcom Alexandra· Chief Financial Officer2,469 sh @ $106.18−$262K↗
  • Mar 30, 26SELLNoci Darlene· Chief Development Officer2,968 sh @ $98.13−$291K↗
  • Mar 30, 26SELLNoci Darlene· Chief Development Officer2,532 sh @ $97.43−$247K↗
  • Mar 26, 26SELLMiller Deborah Ann· Chief Legal Officer2,803 sh @ $99.46−$279K↗
  • Mar 26, 26SELLMiller Deborah Ann· Chief Legal Officer1,757 sh @ $98.21−$173K↗
  • Mar 26, 26SELLMiller Deborah Ann· Chief Legal Officer940 sh @ $97.50−$92K↗
  • Mar 25, 26SELLBalcom Alexandra· Chief Financial Officer13,700 sh @ $100.16−$1.37M↗
  • Mar 24, 26SELLBalcom Alexandra· Chief Financial Officer7,671 sh @ $95.88−$735K↗
  • Mar 24, 26SELLBalcom Alexandra· Chief Financial Officer2,599 sh @ $95.03−$247K↗
  • Mar 24, 26SELLBalcom Alexandra· Chief Financial Officer1,160 sh @ $96.50−$112K↗
  • Mar 13, 26SELLPelish Henry E.· Chief Scientific Officer2,597 sh @ $98.83−$257K↗
  • Mar 13, 26SELLPelish Henry E.· Chief Scientific Officer1,703 sh @ $99.71−$170K↗
🐶 Hiring Signal
No open roles indexed yet — view Nuvalent, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$NUVL
SEC CIK
0001861560
country
US
source
sec_tickers
top tags
NSCLC2Oncology2
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 8m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?